( arameters: patient's global assessment...)Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis,Health

arameters: patient's global assessment, physician's global assessment, patient's assessment of
pain, degree of disability, and level of acute-phase reactant. ACR20 is achieved when there is 20% improvement in the tender and swollen
joint count as well as a 20% improvement in at least three of the five parameters. ACR50 & ACR70 are an extension of these criteria
corresponding to a 50% and 70% improvement respectively.[1]

Notes to Editors:
RAPID Clinical Trials Program
The RAPID series of clinical trials were designed to establish the efficacy and tolerability of CIMZIA(TM) (certolizumab pegol) in the
treatment of rheumatoid arthritis. The RAPID clinical trial programme is composed of two large, international, multi-centre
placebo-controlled studies - RAPID 1 (027) and RAPID 2 (050). In the 52-week RAPID 1 trial, 992 patients were randomly allocated to receive one of three treatment regimens:
* 397 patients received 400 mg lyophilized CIMZIA(TM) at the start of
the study and at weeks two and four, then 200 mg given every two
weeks, together with methotrexate;
* 394 patients received 400 mg lyophilized CIMZIA(TM) every two
weeks, together with methotrexate;
* 201 patients received placebo every two weeks, together with
methotrexate.

In all three arms of the study, the dose of methotrexate was 10 mg per week or greater. Co-primary endpoints for the study RAPID 1 were the ACR20 responder rate at week 24 and the change from baseline in mTSS at week 52. These data on radiographic progression will be presented at a forthcoming rheumatology congress.

24-Week ACR Responses for RAPID 1

+-------------------------------------------------------------------+
| | Placebo & | CIMZIA(TM)) | CIMZIA(TM) |
| | MTX | (certolizumab | (certolizumab pegol) |
| |
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Gabapentin Shown Effective for Fibromyalgia Pain
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
6. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
7. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
8. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
9. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
10. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
11. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression